AstraZeneca to miss its 2027 revenue growth guidance
Resolves: AstraZeneca’s reported 2027 revenue growth is at least 1 percentage point below its 2027 guidance as of 2026-07-11.
user-generated· earnings
AstraZeneca to miss its 2027 revenue growth guidance
Market overview
The trial failure for Wainua, combined with investor skepticism about its pipeline, increases the likelihood that AstraZeneca will fall short of its 2027 revenue growth targets. Analysts may downgrade estimates if confidence in its late-stage programs wanes further.
earnings prediction market
- Implied probability (Yes)
- 75%
- Closes
- 2027-03-31
About this prediction
Resolution criteria
AstraZeneca’s reported 2027 revenue growth is at least 1 percentage point below its 2027 guidance as of 2026-07-11.
Source: user-generated
More earnings markets
- Will cash burn exceed $5M in Q4? — 65% Yes
- Will Venyra beat Q4 2026 revenue consensus of $230M? — 85% Yes
- Will Nuburu secure emergency financing by Q3 end? — 35% Yes
- Will Everpure, Inc. report a non-GAAP EPS beat for the quarter ended June 30, 2026? — 50% Yes
- Will KR miss Q4 operating margin guidance? — 65% Yes
- Will George Risk report Q4 2026 revenue above $13M? — 85% Yes
- Will DCI beat Q4 EPS consensus of $0.88? — 65% Yes
- Will inventory days decrease below 70 by year-end? — 40% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…